Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation Policy FDA

US Regulatory Reads, February 2018: Funding, Digital Health And Program Alignment

  • News
  • David Filmore
    David Filmore

Executive Summary

While the overall FY 2019 Trump administration budget request submitted last month was widely criticized, the high numbers slated for US FDA in the document attracted positive attention in the life-sciences space, and among Medtech Insight readers. Also popular among US regulatory and policy content last month: coverage of a digital-health gathering, program alignment insights and stories on FDA restructuring, federal enforcement and adverse events trends.

Table

View full table

Topics

Tags:
Regulation Policy FDA
Latest Headlines

UK MHRA’s Strategic Approach To AI Will Be ‘Proportionate’ And Fit Well Internationally

Attorney: Proposed Data Privacy Law Would Ultimately Reduce Regulatory Burden

Senseonics Wins Marketing Authorization For Novel Insulin Delivery System

Liquid Biopsy Company Karius Raised $100M To Expand Its Test For Detecting Over 1,000 Pathogens

See All
UsernamePublicRestriction

Register

MT122280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By